vs
BioNexus Gene Lab Corp（BGLC）与CareDx, Inc.（CDNA）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是BioNexus Gene Lab Corp的224.0倍（$108.4M vs $483.8K）。CareDx, Inc.净利率更高（-3.8% vs -214.2%，领先210.4%）。CareDx, Inc.同比增速更快（25.2% vs -80.8%）。过去两年CareDx, Inc.的营收复合增速更高（22.7% vs -54.9%）
BioNexus Gene Lab Corp是一家生物技术企业，主营分子诊断检测、基因分析及相关生命科学解决方案，服务客户涵盖医疗机构、科研机构及个人用户，核心市场主要覆盖东南亚地区。
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
BGLC vs CDNA — 直观对比
营收规模更大
CDNA
是对方的224.0倍
$483.8K
营收增速更快
CDNA
高出106.0%
-80.8%
净利率更高
CDNA
高出210.4%
-214.2%
两年增速更快
CDNA
近两年复合增速
-54.9%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $483.8K | $108.4M |
| 净利润 | $-1.0M | $-4.1M |
| 毛利率 | -0.8% | — |
| 营业利润率 | -213.5% | -5.6% |
| 净利率 | -214.2% | -3.8% |
| 营收同比 | -80.8% | 25.2% |
| 净利润同比 | -197.5% | -104.7% |
| 每股收益（稀释后） | — | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGLCCDNA
| Q4 25 | $483.8K | $108.4M | ||
| Q3 25 | $2.5M | $100.1M | ||
| Q2 25 | $2.3M | $86.7M | ||
| Q1 25 | $2.1M | $84.7M | ||
| Q4 24 | $2.5M | $86.6M | ||
| Q3 24 | $2.6M | $82.9M | ||
| Q2 24 | $2.0M | $92.3M | ||
| Q1 24 | $2.4M | $72.0M |
净利润BGLCCDNA
| Q4 25 | $-1.0M | $-4.1M | ||
| Q3 25 | $-709.0K | $1.7M | ||
| Q2 25 | $-616.2K | $-8.6M | ||
| Q1 25 | $-623.3K | $-10.4M | ||
| Q4 24 | $-348.3K | $87.7M | ||
| Q3 24 | $-1.3M | $-10.6M | ||
| Q2 24 | $199.1K | $-4.6M | ||
| Q1 24 | $-103.8K | $-19.9M |
毛利率BGLCCDNA
| Q4 25 | -0.8% | — | ||
| Q3 25 | 14.8% | — | ||
| Q2 25 | 16.3% | — | ||
| Q1 25 | 16.1% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 15.3% | — |
营业利润率BGLCCDNA
| Q4 25 | -213.5% | -5.6% | ||
| Q3 25 | -27.6% | -0.2% | ||
| Q2 25 | -27.0% | -12.8% | ||
| Q1 25 | -28.9% | -15.8% | ||
| Q4 24 | -16.5% | 97.5% | ||
| Q3 24 | -50.9% | -16.6% | ||
| Q2 24 | 13.1% | -7.9% | ||
| Q1 24 | -3.3% | -31.3% |
净利率BGLCCDNA
| Q4 25 | -214.2% | -3.8% | ||
| Q3 25 | -27.9% | 1.7% | ||
| Q2 25 | -27.3% | -9.9% | ||
| Q1 25 | -29.2% | -12.2% | ||
| Q4 24 | -13.8% | 101.3% | ||
| Q3 24 | -51.1% | -12.8% | ||
| Q2 24 | 10.1% | -5.0% | ||
| Q1 24 | -4.4% | -27.6% |
每股收益（稀释后）BGLCCDNA
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.40 | $0.03 | ||
| Q2 25 | $-0.34 | $-0.16 | ||
| Q1 25 | $-0.04 | $-0.19 | ||
| Q4 24 | $0.55 | $1.60 | ||
| Q3 24 | $-0.75 | $-0.20 | ||
| Q2 24 | $0.11 | $-0.09 | ||
| Q1 24 | $-0.01 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $177.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $8.6M | $303.1M |
| 总资产 | $9.3M | $413.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BGLCCDNA
| Q4 25 | $2.5M | $177.2M | ||
| Q3 25 | — | $194.2M | ||
| Q2 25 | — | $186.3M | ||
| Q1 25 | — | $230.9M | ||
| Q4 24 | $2.9M | $260.7M | ||
| Q3 24 | — | $240.9M | ||
| Q2 24 | — | $228.9M | ||
| Q1 24 | — | $215.9M |
总债务BGLCCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
股东权益BGLCCDNA
| Q4 25 | $8.6M | $303.1M | ||
| Q3 25 | $6.8M | $311.1M | ||
| Q2 25 | $7.5M | $327.4M | ||
| Q1 25 | $7.8M | $379.3M | ||
| Q4 24 | $8.3M | $378.4M | ||
| Q3 24 | $9.4M | $273.2M | ||
| Q2 24 | $9.5M | $264.7M | ||
| Q1 24 | $9.3M | $256.2M |
总资产BGLCCDNA
| Q4 25 | $9.3M | $413.2M | ||
| Q3 25 | $7.6M | $432.3M | ||
| Q2 25 | $9.4M | $444.3M | ||
| Q1 25 | $9.5M | $489.6M | ||
| Q4 24 | $10.4M | $491.1M | ||
| Q3 24 | $11.0M | $477.0M | ||
| Q2 24 | $11.1M | $466.8M | ||
| Q1 24 | $11.2M | $452.4M |
负债/权益比BGLCCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $961.1K | $21.4M |
| 自由现金流经营现金流 - 资本支出 | $960.1K | — |
| 自由现金流率自由现金流/营收 | 198.5% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9M | — |
8季度趋势，按日历期对齐
经营现金流BGLCCDNA
| Q4 25 | $961.1K | $21.4M | ||
| Q3 25 | $-1.2M | $37.4M | ||
| Q2 25 | $-737.9K | $9.9M | ||
| Q1 25 | $-824.1K | $-26.6M | ||
| Q4 24 | $219.2K | $21.9M | ||
| Q3 24 | $-1.6M | $12.5M | ||
| Q2 24 | $-672.3K | $18.9M | ||
| Q1 24 | $-37.2K | $-15.3M |
自由现金流BGLCCDNA
| Q4 25 | $960.1K | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-759.4K | — | ||
| Q1 25 | $-833.1K | — | ||
| Q4 24 | $215.2K | — | ||
| Q3 24 | $-1.8M | — | ||
| Q2 24 | $-674.1K | — | ||
| Q1 24 | $-59.1K | — |
自由现金流率BGLCCDNA
| Q4 25 | 198.5% | — | ||
| Q3 25 | -48.9% | — | ||
| Q2 25 | -33.6% | — | ||
| Q1 25 | -39.0% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | -68.5% | — | ||
| Q2 24 | -34.1% | — | ||
| Q1 24 | -2.5% | — |
资本支出强度BGLCCDNA
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 7.6% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.9% | — |
现金转化率BGLCCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | 22.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.38× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BGLC
暂无分部数据
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
